If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhoenix Group Holdings Regulatory News (PHNX)

  • There is currently no data for PHNX

Response to FCA Statement

28 Mar 2014 16:43

RNS Number : 5058D
Phoenix Group Holdings
28 March 2014
 



 

Phoenix Group Holdings ("Phoenix") response to FCA statement

 

 

Phoenix notes the statement issued by the FCA earlier today regarding a thematic review into the fair treatment of longstanding or legacy customers within closed life funds.

 

Although little detail has been provided regarding the scope and nature of any review, Phoenix makes the following observations:

 

· The FCA has stated that the review will not consider the suitability of historic advice, nor will it require a review of individual policies.

· The review will look at the level of servicing provided to policyholders whose policies are managed within closed life funds. Phoenix welcomes this review as we continue to look for areas where we can deliver better levels of customer service. We have achieved significant policy administration migrations to newer and better systems resulting in improved customer service. We regularly review our full product set to ensure it is operating as intended and remain committed to maintaining our focus on the governance of our products.

· Phoenix does not write new products (other than vesting annuities) and therefore we do not believe that any review of cross-subsidisation (in particular of the cost of new products) would be relevant to Phoenix.

· Furthermore, should the review look at the charging structures on historic policies, we are confident that our historic charging structures, including exit charges, have been compliant and in accordance with our commitments to our policyholders.

 

The press speculation regarding the thematic review follows two previous issues which have impacted the life assurance market over the last two weeks:

 

· The first of these issues was the announcement by the Chancellor in the Budget last week that policyholders would no longer be required to convert their pensions into an annuity on retirement. As explained in our full year results announcement, issued on Wednesday 26 March, we believe that this change will not have a material impact on Phoenix.

· Yesterday the Government announced a cap for all workplace pension schemes for auto enrolment. It is estimated that the cost of applying the cap to our schemes could have a maximum impact on our MCEV of £40 million.

 

In response to the statement from the FCA, Clive Bannister (Phoenix CEO) commented:

 

"Policyholders are central to everything that we do at Phoenix and we remain focussed on improving our performance and service. We aim to treat our policyholders fairly at all times. Operationally, we continue to streamline and modernise the business for the benefit of our policyholders. For example, in 2013 we increased the distributable estate by £565 million, with around 115,000 policyholders benefiting from £157 million of estate distributed in that year.

 

As our recent full-year results amply demonstrate, Phoenix is performing extremely well. This week we announced our highest ever cash generation (£817 million) and MCEV of £2.4 billion. We remain confident in the outlook for the Group.

 

We note that the review will not apply "current standards retrospectively" but is designed to "assess whether there is an issue that requires any action".

 

We will of course co-operate fully with any review conducted by the FCA."

 

We will update the market when we have greater clarity on the scope and nature of the review.

 

 

 

 

Enquiries

 

Investors / analysts

Sam Perowne

Head of Investor Relations, Phoenix Group

+44 (0)20 3735 0021

 

Media

Neil Bennett, Peter Ogden, Tom Eckersley,

Maitland

+44 (0)20 7379 5151

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRQKFDNABKDFNB
Date   Source Headline
10th Apr 20249:43 amRNSDirector/PDMR Shareholding
9th Apr 20248:33 amRNSDirector/PDMR Shareholding
8th Apr 20242:15 pmRNSNotice of AGM
3rd Apr 20241:02 pmRNSDirector/PDMR Shareholding
2nd Apr 20245:26 pmRNSTotal Voting Rights
2nd Apr 20244:45 pmRNSDirector/PDMR Shareholding
28th Mar 20245:40 pmRNSDirector/PDMR Shareholding
27th Mar 20244:20 pmRNSAnnual Financial Report
27th Mar 20242:45 pmRNSDirector/PDMR Shareholding
22nd Mar 20247:00 amRNS2023 Annual Financial Report
6th Mar 20242:00 pmRNSDirector/PDMR Shareholding
1st Mar 20249:35 amRNSTotal Voting Rights
6th Feb 20245:17 pmRNSDirector/PDMR Shareholding
2nd Feb 202410:56 amRNSTotal Voting Rights
1st Feb 20247:00 amRNS2023 Trading Statement
8th Jan 20245:09 pmRNSDirector/PDMR Shareholding
2nd Jan 20243:15 pmRNSTotal Voting Rights
11th Dec 20236:13 pmRNSBlock listing Interim Review
6th Dec 20234:28 pmRNSDirector/PDMR Shareholding
5th Dec 202311:42 amRNSFinal Result of Tender Offer
5th Dec 202310:22 amRNSIndicative Result of Tender Offer
5th Dec 20237:10 amRNSPublication of Final Terms
1st Dec 202311:46 amRNSTotal Voting Rights
28th Nov 20235:46 pmRNSIssue of Debt and Tender Maximum Acceptance Amount
27th Nov 20238:20 amRNSTender Offers and New Issue
24th Nov 202311:05 amRNSDirector Declaration
23rd Nov 20232:00 pmRNSPublication of Supplementary Prospectus
23rd Nov 202310:00 amRNSDirectorate Change
13th Nov 20237:00 amRNSUpgrade of near-term cash generation targets
7th Nov 20235:10 pmRNSDirector/PDMR Shareholding
1st Nov 20232:07 pmRNSDirector/PDMR Shareholding
31st Oct 20232:30 pmRNSHolding(s) in Company
25th Oct 20231:17 pmRNSDirector/PDMR Shareholding
25th Oct 20231:16 pmRNSDirector/PDMR Shareholding
9th Oct 202312:40 pmRNSDirector/PDMR Shareholding
9th Oct 202311:20 amRNSDirector/PDMR Shareholding
4th Oct 202310:00 amRNSBoard Changes
2nd Oct 20233:00 pmRNSPublication of Supplementary Prospectus
2nd Oct 20231:35 pmRNSTotal Voting Rights
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
28th Sep 20232:46 pmRNSDirector/PDMR Shareholding
28th Sep 202312:49 pmRNSAvailability of Interim Financial Report
28th Sep 20237:00 amRNSInterim Financial Report
18th Sep 20237:00 amRNS2023 Interim Results
14th Sep 202310:00 amRNSHY23 reporting update
8th Sep 20239:33 amRNSDirector/PDMR Shareholding
1st Sep 20231:29 pmRNSTotal Voting Rights
9th Aug 20235:04 pmRNSDirector/PDMR Shareholding
1st Aug 20233:16 pmRNSTotal Voting Rights
7th Jul 20233:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.